ArticleCancers2021

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells.

Marta Celegato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.